201911 - Tripodi - Immunoterapia specifica alla luce della e-mobile health?Asmallergie
1. The document discusses using digital solutions like mobile health to improve allergen immunotherapy (AIT) by combining clinical research data and mobile health for AIT prescription.
2. It proposes the "@IT-2020" process, a flexible 4-step modular approach for prescribing AIT for pollen allergy patients in Southern Europe/Mediterranean countries, to be validated in a pilot study (2016-2017) and multicenter study (2018-2019).
3. The 4 diagnostic steps of "@IT-2020" and validation testing are described, aiming to determine genuine vs false sensitization, primary sensitization, and the relationship between sensitization and symptoms to guide personalized AIT prescription.
201911 - Rossi - L'asma grave è sempre “grave”?Asmallergie
This document discusses a study of 437 patients with severe asthma (GINA step V) in Italy. The main findings were:
- The average annual exacerbation rate was 3.75.
- The mean blood eosinophil level was 536.7 cells/mcL and average serum total IgE was 470.3 kU/L.
- 64% were on regular oral corticosteroids, 57% with omalizumab and 11.2% with mepolizumab.
- The most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Bronchiectasis was associated with more frequent severe exacerbations.
201911 - Tripodi - Immunoterapia specifica alla luce della e-mobile health?Asmallergie
1. The document discusses using digital solutions like mobile health to improve allergen immunotherapy (AIT) by combining clinical research data and mobile health for AIT prescription.
2. It proposes the "@IT-2020" process, a flexible 4-step modular approach for prescribing AIT for pollen allergy patients in Southern Europe/Mediterranean countries, to be validated in a pilot study (2016-2017) and multicenter study (2018-2019).
3. The 4 diagnostic steps of "@IT-2020" and validation testing are described, aiming to determine genuine vs false sensitization, primary sensitization, and the relationship between sensitization and symptoms to guide personalized AIT prescription.
201911 - Rossi - L'asma grave è sempre “grave”?Asmallergie
This document discusses a study of 437 patients with severe asthma (GINA step V) in Italy. The main findings were:
- The average annual exacerbation rate was 3.75.
- The mean blood eosinophil level was 536.7 cells/mcL and average serum total IgE was 470.3 kU/L.
- 64% were on regular oral corticosteroids, 57% with omalizumab and 11.2% with mepolizumab.
- The most common comorbidities were rhinitis, nasal polyposis, and bronchiectasis. Bronchiectasis was associated with more frequent severe exacerbations.
201911 - Conte - Asma eosinofilico: i farmaci biologici che contrastano l'azi...Asmallergie
This document summarizes a presentation about eosinophilic asthma and biological drugs that target interleukin-5 (IL-5). It discusses the role of eosinophils and IL-5 in asthma, clinical studies of anti-IL-5 drugs like mepolizumab and benralizumab, and real-world experience with these therapies. The presentation covers the pathophysiology of eosinophilic asthma, how anti-IL-5 drugs work, results from major clinical trials showing reduced exacerbations and oral corticosteroid use, and insights from real-world studies on treatment response and outcomes. It emphasizes the importance of patient phenotypes and endotypes in guiding therapy selection for severe asthma.
201911 - Villalta - Novità in ambito di diagnostica molecolare nella sensibil...Asmallergie
This document discusses advances in molecular diagnostics for mite sensitization. It begins with a brief history of allergy to house dust mites and an overview of the major allergenic molecules from mites, including Der p 1, Der p 2, and Der p 23. It describes the concept of "molecular spreading" where the IgE response spreads from initial sensitization to major allergens to include other milder allergens over time. The document then covers classical and molecular diagnostic techniques for mite allergy. It concludes by discussing the potential predictive role of antibody patterns to different mite allergens.
20181110 - Polla - Nuove associazioni inalatorie nella terapia dell’asma bron...Asmallergie
This document discusses new inhaler combinations for treating asthma. It summarizes several clinical studies that evaluated the efficacy of combining inhaled corticosteroids and long-acting muscarinic antagonists to control asthma symptoms. One study of over 5,000 patients found that combining these drugs reduced the risk of exacerbations compared to inhaled corticosteroids alone. The document also references guidelines from GINA that recommend stepwise treatment with inhaled corticosteroids and adding long-acting beta-agonists or tiotropium for uncontrolled asthma.
201911 - Conte - Asma eosinofilico: i farmaci biologici che contrastano l'azi...Asmallergie
This document summarizes a presentation about eosinophilic asthma and biological drugs that target interleukin-5 (IL-5). It discusses the role of eosinophils and IL-5 in asthma, clinical studies of anti-IL-5 drugs like mepolizumab and benralizumab, and real-world experience with these therapies. The presentation covers the pathophysiology of eosinophilic asthma, how anti-IL-5 drugs work, results from major clinical trials showing reduced exacerbations and oral corticosteroid use, and insights from real-world studies on treatment response and outcomes. It emphasizes the importance of patient phenotypes and endotypes in guiding therapy selection for severe asthma.
201911 - Villalta - Novità in ambito di diagnostica molecolare nella sensibil...Asmallergie
This document discusses advances in molecular diagnostics for mite sensitization. It begins with a brief history of allergy to house dust mites and an overview of the major allergenic molecules from mites, including Der p 1, Der p 2, and Der p 23. It describes the concept of "molecular spreading" where the IgE response spreads from initial sensitization to major allergens to include other milder allergens over time. The document then covers classical and molecular diagnostic techniques for mite allergy. It concludes by discussing the potential predictive role of antibody patterns to different mite allergens.
20181110 - Polla - Nuove associazioni inalatorie nella terapia dell’asma bron...Asmallergie
This document discusses new inhaler combinations for treating asthma. It summarizes several clinical studies that evaluated the efficacy of combining inhaled corticosteroids and long-acting muscarinic antagonists to control asthma symptoms. One study of over 5,000 patients found that combining these drugs reduced the risk of exacerbations compared to inhaled corticosteroids alone. The document also references guidelines from GINA that recommend stepwise treatment with inhaled corticosteroids and adding long-acting beta-agonists or tiotropium for uncontrolled asthma.
5. La correlazione fra ASMA ed ESERCIZIO FISICO risale
alla seconda metà del II° secolo Areteo di Cappadocia.
Il primo riferimento di ASMA INDOTTA DA ESERCIZIO
FISICO (EIA) è attribuito a John Floyer 1698
Negli anni 60-70 soggetti affetti da asma bronchiale
venivano considerati non idonei all’attività sportiva
agonistica (F.M.I. 1961)
Nel 2013 ATS, AAAAI/ACAAI decise di definire EIBa
l’insorgenza di ostruzione bronchiale dopo esercizio
fisico in pazienti affetti da asma e EIBwa l ‘insorgenza di
ostruzione bronchiale in pazienti senza segni o sintomi di
asma
*
6. Two Hypotheses:
Heat loss & the re-warming of the airways
leading to vascular engorgement =
bronchoconstriction (McFadden & Gilbert, 1994;
Anderson & Daviskas, 2000).
Dehydration of airways = changes initiating
epithelial and mast cell activation =
inflammatory process (McFadden & Gilbert; Anderson &
Daviskas)
*
14. The EVH test has a key role in the diagnostic algorithm for EIB testing in athletes. It undoubtedly
detects moderate to severe AHR in susceptible athletes, and its greatest value appears to lie in its
negative predictive value. However, the wide sensitivity and specificity indices and poor repeatability in
mild to moderate cases preclude EVH being termed a ‘gold standard’ test for EIB.
20. *
*Ottimizzare il trattamento di fondo
*Curare tutte le eventuali comorbilità
*Informare accuratamento l’atleta e lo staff
*Assicurare sempre la disponibilità dei farmaci d
emergenza
*Collaborare con la WADA
*Assicurarsi che l’ atleta assuma il farmaco ( app?)
*Prevenzione delle infezioni
21. *
*RISCALDAMENTO PRE GARA
PRERISCALDAMENTO DI ALMENO 10
min. PRIMA DELL’INIZIO E ALLA FINE
DELL’ATTIVITA’ SPORTIVA
ALLENAMENTO INTERMITTENTE:
BREVI SPRINT DI INTENSITA’
CRESCENTE, IN NUMERO DI 10-12
DELLA DURATA DI 20-30 sec. L’UNO
INTERCALATI DA IDENTICI PERIODI DI
RECUPERO
ALLENAMENTO PER ELEVARE IL
LAVORO ANAEROBICO
22. Adeguato riscaldamento
Evitare il prolungato
stazionamento nelle piscine
coperte
Ridurre lo stazionamento in
acqua a bordo della piscine
Evitare piscine con acqua
troppo calda
Se possibile evitare gare
nell’immediato periodo post-
clorazione
33. *Iperventilazione
*Aria fredda e secca
*Vento
*Riduzione inquinanti
*Riduzione aeroallergeni
*ASMA MODERATO
*EVITARE RAPIDI
CAMBIAMENTI DI
DISLIVELLO
*PROTEGGERSI LA BOCCA
IN CASO DI VENTO
*